TNFSF11 and Miyoshi myopathy: Bisphosphonates, especially zoledronic acid, and denosumab, a monoclonal antibody binding to the receptor activator of nuclear factor kappa-Β ligand (RANKL), are the mainstay of treatment for MM-related bone disease [3].